Investigational drug · Phase 2
BFB-101
Also called: AAV9-CBh-AP4B1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BFB-101"
First trial start
2025
Aug 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BFB-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- HSP
- Hereditary Spastic Paraplegia
- Hereditary Spastic Paraparesis
- Hereditary Spastic Paraplegia Type 50
- Hereditary Spastic Paraplegia Type 47
- Hereditary Spastic Paraplegia Type 51
- Hereditary Spastic Paraplegia Type 52
- SPG47
- AP4B1
- Neurogenetic Disorders
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BFB-101" as an intervention, largest first.
- Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)Not yet recruiting
BlackfinBio LtdIndustry
NCT06948019 · 5 participants (planned) · Start Aug 2025 · Primary completion Aug 2030
Drug: BFB-101 (AAV9-CBh-AP4B1) · For: HSP; Hereditary Spastic Paraplegia; Hereditary Spastic Paraparesis and 10 more
Sites: Boston, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.